Edwards Lifesciences Corp (EW)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 5,724,300 | 5,872,600 | 5,999,100 | 6,143,400 | 6,004,800 | 5,819,000 | 5,657,100 | 5,500,800 | 5,382,400 | 5,363,800 | 5,355,000 | 5,357,100 | 5,232,500 | 5,094,500 | 4,925,200 | 4,474,200 | 4,386,300 | 4,368,700 | 4,321,800 | 4,483,700 |
Total current assets | US$ in thousands | 6,285,400 | 6,727,700 | 4,516,000 | 4,170,500 | 4,035,700 | 4,067,500 | 3,647,000 | 3,257,200 | 3,095,800 | 3,513,900 | 3,263,100 | 3,241,300 | 3,180,700 | 3,515,500 | 3,322,900 | 3,069,200 | 3,091,000 | 2,980,400 | 2,690,300 | 2,507,900 |
Total current liabilities | US$ in thousands | 1,505,200 | 1,944,100 | 1,217,000 | 1,110,800 | 1,195,400 | 1,238,900 | 1,157,200 | 1,082,000 | 1,022,400 | 917,900 | 969,100 | 949,900 | 1,032,300 | 966,500 | 886,200 | 799,000 | 893,900 | 846,300 | 873,200 | 746,900 |
Working capital turnover | 1.20 | 1.23 | 1.82 | 2.01 | 2.11 | 2.06 | 2.27 | 2.53 | 2.60 | 2.07 | 2.33 | 2.34 | 2.44 | 2.00 | 2.02 | 1.97 | 2.00 | 2.05 | 2.38 | 2.55 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $5,724,300K ÷ ($6,285,400K – $1,505,200K)
= 1.20
The working capital turnover of Edwards Lifesciences Corp has shown fluctuating trends over the period under consideration. The ratio peaked at 2.60 as of December 31, 2022, indicating that the company was able to generate $2.60 in revenue for every dollar of working capital invested. This suggests efficient utilization of its working capital during that period.
However, the working capital turnover ratio started declining after December 2022, reaching a low of 1.20 by December 31, 2024. This downward trend indicates a potential decrease in the company's efficiency in generating revenue from its working capital.
Overall, it is essential for Edwards Lifesciences Corp to continuously monitor and manage its working capital effectively to ensure optimal operational performance and sustainable growth in the long run.
Peer comparison
Dec 31, 2024
See also:
Edwards Lifesciences Corp Working Capital Turnover (Quarterly Data)